<DOC>
	<DOCNO>NCT01154361</DOCNO>
	<brief_summary>This multicenter study recruit patient angioedema induced ACEI . Open-label treatment subcutaneous Icatibant compare historic group 47 patient ACE inhibitor induce angioedema investigator previously treat investigator center current `` standard '' therapy ( 250 mg methylprednisolon 2 mg clemastine ) . In case fast progression edema application study-drug , second application icatibant could necessary . Rescue medication intervention .</brief_summary>
	<brief_title>AMelioration Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study</brief_title>
	<detailed_description>Sudden occurrence subcutaneous submucosal non-itchy swelling , so-called angioedema , well know side effect angiotensin-converting enzyme inhibitor ( ACEi ) , may become life-threatening upper airway involve . To note , ACEi induce angioedema always locate head neck region . The pathophysiology ACE inhibitor ( ACEi ) induce angioedema likely resembles hereditary angioedema ( HAE ) , i.e . mainly mediate bradykinin induced activation vascular bradykinin B2 receptor ( BKR-2 ) . In contrast increase bradykinin generation HAE , treatment ACEi decrease bradykinin degradation plasma increase biological activity bradykinin . The current pharmacotherapy ACEi induce angioedema satisfactory . Antihistamines corticosteroid may effective treatment urticaria cutaneous edema itchy , theoretically ineffective hence superfluous bradykinin induce angioedema . However , glucocorticoid still belong standard treatment angioedema . We hypothesize BKR-2 antagonist icatibant might effective therapy ACEi-induced angioedema . Patients ACEi induce angioedema , locate upper aero-digestive tract randomize treat either icatibant plazebo cortisone clemastin plazebo .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Bradykinin B2 Receptor Antagonists</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>Age &gt; = 18 &lt; 85 year Patient currently treat ACEI Patient must acute angioedema attack cause ACEI Treatment administrate within 10 hrs onset ACEI Patient angioedema head /or neck ( face , lip , cheek , tongue , soft palate/uvula , pharynx larynx ) At least one moderate severe severe angioedema symptom assess investigator , require medical intervention Signed write Informed Consent Form Diagnosis angioedema cause ACEI : e.g . hereditary angioedema ( C1INH deficiency ) , allergy , anaphylaxis , insect bite , trauma , infection , abscess , tumor , postradiation postoperative process related salivary gland others unlikely ACEI cause angioedema Participation clinical trial another investigational medicinal product ( IMP ) within 30 day Patients acute urticaria Patients medical history angioedema take ACEI Patients acute rash hive face somewhere else Unstable angina acute myocardial infarction Acute heart failure Serious concomitant illnesses physician considers contraindication participation trial Pregnancy and/or breastfeed Mental condition render patient , opinion investigator , unable understand nature , scope possible consequence study ; Unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikely complete study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>ACE inhibitor induce angioedema</keyword>
	<keyword>Bradykinin</keyword>
	<keyword>Non-itching edema</keyword>
	<keyword>Non-allergic angioedema</keyword>
	<keyword>Quincke edema</keyword>
	<keyword>Drug induce angioedema</keyword>
	<keyword>Bradykinin B2 receptor antagonist</keyword>
	<keyword>Icatibant</keyword>
	<keyword>HOE 140</keyword>
</DOC>